background


Product Information:

Ivonescimab

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .

Cat. No.: EX-A15454    Purity: >98%
Chemical
Chemical structure of Ivonescimab


For research only, Do not use for Human!

SizeUnit Price (US$)StockQuantityOrder
25mg1950in-stock
50mg3350in-stock
100mg4950in-stock
500mgget quotein-stock
1gget quotein-stock


SynonymsAK112
CAS No.2428381-53-5
Purity>98%
ColorColorless to light yellow
StateLiquid
Shelf Life>3 years if stored properly
StorageStore at 4℃
ShippingShipping with ice bag
 
 
Reference:  

[1]. Coward J, et al. Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study. Journal for Immuno Therapy of Cancer 2021;9:

[2]. Zhong T, et al. AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies. Journal for Immuno Therapy of Cancer. 2022;10:

[3]. Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. Journal for Immuno Therapy of Cancer. 2022;10:e005517.

[4]. Dhillon S. Ivonescimab: First Approval. Drugs. 2024 Sep;84(9):1135-1142.

[5]. Fang W, et al. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial. JAMA. 2024 Aug 20;332(7):561-570.

CoACoA of Ivonescimab

KEYWORDS: buy Ivonescimab | Ivonescimab supplier | purchase | cost | manufacturer | order | distributor | buy 2428381-53-5 | 2428381-53-5 supplier